Vanda Pharmaceuticals Inc (VNDA)
5.09
+0.15
(+3.04%)
USD |
NASDAQ |
Nov 22, 16:00
5.105
+0.02
(+0.29%)
After-Hours: 20:00
Vanda Pharmaceuticals Cash from Financing (Quarterly)
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2022 | 0.605M |
| September 30, 2022 | 0.004M |
| June 30, 2022 | 0.125M |
| March 31, 2022 | |
| December 31, 2021 | 1.041M |
| September 30, 2021 | 0.371M |
| June 30, 2021 | 0.289M |
| March 31, 2021 | 1.849M |
| December 31, 2020 | 1.432M |
| September 30, 2020 | 0.123M |
| June 30, 2020 | 3.60M |
| March 31, 2020 | 0.479M |
| December 31, 2019 | 2.116M |
| September 30, 2019 | 0.558M |
| June 30, 2019 | 3.411M |
| March 31, 2019 | 0.179M |
| December 31, 2018 | 0.792M |
| September 30, 2018 | 0.112M |
| June 30, 2018 | 2.488M |
| March 31, 2018 | 103.73M |
| December 31, 2017 | 0.081M |
| September 30, 2017 | 0.768M |
| June 30, 2017 | 2.193M |
| March 31, 2017 | 2.209M |
| December 31, 2016 | 0.75M |
| Date | Value |
|---|---|
| September 30, 2016 | 5.962M |
| June 30, 2016 | 1.015M |
| March 31, 2016 | 0.024M |
| December 31, 2015 | -0.001M |
| September 30, 2015 | 3.579M |
| June 30, 2015 | 0.592M |
| March 31, 2015 | -0.079M |
| December 31, 2014 | 87.49M |
| September 30, 2014 | 0.198M |
| June 30, 2014 | 0.032M |
| March 31, 2014 | 2.011M |
| December 31, 2013 | 0.441M |
| September 30, 2013 | 48.82M |
| June 30, 2013 | 0.794M |
| March 31, 2013 | -0.193M |
| December 31, 2012 | 0.012M |
| September 30, 2012 | 0.00 |
| June 30, 2012 | 0.00 |
| March 31, 2012 | 0.00 |
| December 31, 2011 | 0.02M |
| September 30, 2011 | 0.005M |
| June 30, 2011 | 0.00 |
| March 31, 2011 | 0.00 |
| December 31, 2010 | 1.347M |
| September 30, 2010 | 0.042M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
0.004M
Minimum
Sep 2022
3.60M
Maximum
Jun 2020
1.003M
Average
0.542M
Median
Cash from Financing (Quarterly) Benchmarks
| Zevra Therapeutics Inc | 64.76M |
| Black Diamond Therapeutics Inc | -0.252M |
| Edgewise Therapeutics Inc | 3.333M |
| NovaBay Pharmaceuticals Inc | 2.089M |
| Palatin Technologies Inc | -0.127M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -14.58M |
| Cash from Investing (Quarterly) | 12.06M |
| Free Cash Flow | -18.20M |
| Free Cash Flow Per Share (Quarterly) | -0.253 |
| Free Cash Flow to Equity (Quarterly) | -14.74M |
| Free Cash Flow to Firm (Quarterly) | -14.74M |
| Free Cash Flow Yield | -6.17% |